ADX88178

{{cs1 config|name-list-style=vanc|display-authors=6}} {{Infobox drug | IUPAC_name = 5-methyl-N-(4-methylpyrimidin-2-yl)-4-(1H-pyrazol-4-yl)-1,3-thiazol-2-amine | image = ADX88178.svg | image_class = skin-invert-image | width =

| tradename = | routes_of_administration =

| C=12 | H=12 | N=6 | S=1 | smiles = CC1=NC(=NC=C1)NC2=NC(=C(S2)C)C3=CNN=C3 | StdInChI = 1S/C12H12N6S/c1-7-3-4-13-11(16-7)18-12-17-10(8(2)19-12)9-5-14-15-6-9/h3-6H,1-2H3,(H,14,15)(H,13,16,17,18) | StdInChIKey = MIQNXKWDQRNHAU-UHFFFAOYSA-N }}

'''ADX88178''' is an experimental drug that acts as a positive allosteric modulator for the glutamate receptor mGluR4. It was developed as a potential medication for the treatment of Parkinson's disease but had mixed results in animal studies, improving dyskinesia but worsening psychosis-like symptoms. However it has antiinflammatory effects in brain tissue which may make it useful for other indications.<ref>{{cite journal | vauthors = Le Poul E, Boléa C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, Hodge LM, Smith KM, DiLella AG, Liverton N, Hess F, Browne SE, Reynolds IJ | title = A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 343 | issue = 1 | pages = 167–177 | date = October 2012 | pmid = 22787118 | doi = 10.1124/jpet.112.196063 }}</ref><ref>{{cite journal | vauthors = Kalinichev M, Le Poul E, Boléa C, Girard F, Campo B, Fonsi M, Royer-Urios I, Browne SE, Uslaner JM, Davis MJ, Raber J, Duvoisin R, Bate ST, Reynolds IJ, Poli S, Celanire S | title = Characterization of the novel positive allosteric modulator of the metabotropic glutamate receptor 4 ADX88178 in rodent models of neuropsychiatric disorders | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 350 | issue = 3 | pages = 495–505 | date = September 2014 | pmid = 24947466 | doi = 10.1124/jpet.114.214437 | pmc = 4152882 }}</ref><ref>{{cite journal | vauthors = Ponnazhagan R, Harms AS, Thome AD, Jurkuvenaite A, Gogliotti R, Niswender CM, Conn PJ, Standaert DG | title = The Metabotropic Glutamate Receptor 4 Positive Allosteric Modulator ADX88178 Inhibits Inflammatory Responses in Primary Microglia | journal = Journal of Neuroimmune Pharmacology | volume = 11 | issue = 2 | pages = 231–237 | date = June 2016 | pmid = 26872456 | doi = 10.1007/s11481-016-9655-z | pmc = 4848139 }}</ref><ref>{{cite journal | vauthors = Abulwerdi G, Stoica BA, Loane DJ, Faden AI | title = Putative mGluR4 positive allosteric modulators activate G<sub>i</sub>-independent anti-inflammatory mechanisms in microglia | journal = Neurochemistry International | volume = 138 | article-number = 104770 | date = September 2020 | pmid = 32454165 | doi = 10.1016/j.neuint.2020.104770 | pmc = 7392812 }}</ref><ref>{{cite journal | vauthors = Frouni I, Kwan C, Bédard D, Kang W, Hamadjida A, Nuara SG, Gourdon JC, Huot P | title = Effect of the mGlu<sub>4</sub> positive allosteric modulator ADX-88178 on parkinsonism, psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset | journal = Psychopharmacology | volume = 240 | issue = 10 | pages = 2093–2099 | date = October 2023 | pmid = 37516708 | doi = 10.1007/s00213-023-06428-1 }}</ref><ref>{{cite journal | vauthors = Wang X, Wang M, Xu T, Feng Y, Shao Q, Han S, Chu X, Xu Y, Lin S, Zhao Q, Wu B | title = Structural insights into dimerization and activation of the mGlu2-mGlu3 and mGlu2-mGlu4 heterodimers | journal = Cell Research | volume = 33 | issue = 10 | pages = 762–774 | date = October 2023 | pmid = 37286794 | doi = 10.1038/s41422-023-00830-2 | pmc = 10543438 }}</ref>

== References == {{Reflist}}

Category:Experimental drugs Category:Pyrimidines Category:Pyrazoles Category:Thiazoles